| Literature DB >> 36158745 |
Adam Hubler1, Daniel V Wakefield1,2, Lydia Makepeace1, Matt Carnell3, Ankur M Sharma1,4, Bo Jiang1, Austin P Dove5, Wesley B Garner1, Drucilla Edmonston1, John G Little3, Esra Ozdenerol6, Ryan B Hanson6, Michelle Y Martin7, Arash Shaban-Nejad8, Maria Pisu9, David L Schwartz1,7.
Abstract
Purpose: Radiation treatment interruption associated with unplanned hospitalization remains understudied. The intent of this study was to benchmark the frequency of hospitalization-associated radiation therapy interruptions (HARTI), characterize disease processes causing hospitalization during radiation, identify factors predictive for HARTI, and localize neighborhood environments associated with HARTI at our academic referral center. Methods and Materials: This retrospective review of electronic health records provided descriptive statistics of HARTI event rates at our institutional practice. Uni- and multivariable logistic regression models were developed to identify significant factors predictive for HARTI. Causes of hospitalization were established from primary discharge diagnoses. HARTI rates were mapped according to patient residence addresses.Entities:
Year: 2022 PMID: 36158745 PMCID: PMC9489733 DOI: 10.1016/j.adro.2022.101041
Source DB: PubMed Journal: Adv Radiat Oncol ISSN: 2452-1094
Study cohort characteristics and hospitalization-associated RT interruption likelihood
| Number (%) | Frequency of hospitalization-associated RT interruption, n (%) | |
|---|---|---|
| 3729 | 197 (5.3) | |
| Male | 1664 (44.6) | 6.0 |
| Female | 2065 (55.4) | 4.7 |
| 61.2 | ||
| <65 | 2195 (58.9) | 5.1 |
| ≥65 | 1534 (41.1) | 5.6 |
| White | 2032 (54.5) | 4.4 |
| African-American | 1577 (42.3) | 6.3 |
| Other | 120 (3.2) | 6.7 |
| Hispanic | 50 (1.3) | 6.0 |
| Non-Hispanic | 3540 (94.9) | 5.2 |
| Unknown | 139 (3.7) | 7.9 |
| Married | 1967 (52.7) | 4.3 |
| Unmarried | 1648 (44.2) | 6.4 |
| Unknown | 114 (3.1) | 5.3 |
| Low (<$34k) | 1012 (27.1) | 4.4 |
| Middle ($34-67k) | 1532 (41.1) | 5.6 |
| High (>$67k) | 1149 (30.8) | 5.7 |
| Unknown | 36 (1.0) | 5.6 |
| Rural not by metro | 114 (3.0) | 0.9 |
| Rural by metro | 201 (5.4) | 3.0 |
| Metro | 3428 (91.6) | 5.6 |
| 0-5 | 1108 (29.9) | 6.6 |
| 6-10 | 1175 (31.7) | 5.6 |
| 11-15 | 503 (13.6) | 3.8 |
| 16-20 | 220 (5.9) | 6.9 |
| 21-30 | 253 (6.8) | 4.8 |
| 31-40 | 110 (3.0) | 1.9 |
| >40 | 337 (9.1) | 3.3 |
| Commercial | 1794 (48.1) | 3.5 |
| Medicare | 1503 (40.3) | 6.3 |
| Medicaid/no insurance | 432 (11.6) | 9.0 |
| Medicaid | 221 (5.9) | 7.7 |
| No insurance | 211 (5.7) | 10.4 |
| Breast | 974 (26.1) | 1.7 |
| Prostate | 413 (11.1) | 3.4 |
| Lung | 353 (9.5) | 10.8 |
| Gynecologic | 226 (6.1) | 6.2 |
| Head and neck | 402 (10.8) | 10.7 |
| Gastrointestinal | 238 (6.4) | 5.0 |
| Central nervous system | 148 (4.0) | 4.7 |
| Metastasis | 490 (13.1) | 4.1 |
| Skin | 123 (3.3) | 5.7 |
| Soft tissue | 53 (1.4) | 3.8 |
| Hematologic | 146 (3.9) | 2.7 |
| Other | 163 (4.4) | 13.4 |
| Nonwinter (March-October) | 2455 (65.8) | 5.7 |
| Winter (November-February) | 1274 (34.2) | 4.6 |
| 1-5 | 421 (11.3) | 1.2 |
| 6-10 | 494 (13.2) | 5.7 |
| 11-15 | 195 (5.2) | 5.1 |
| 16-20 | 586 (15.7) | 2.2 |
| 21-25 | 368 (9.9) | 4.6 |
| 26-30 | 976 (26.2) | 7.0 |
| >30 | 689 (18.5) | 8.1 |
RT, radiation therapy
Denotes statistical significance
Primary causes of hospitalization
| Number (%) | |
|---|---|
| 175 (100) | |
| Malnutrition/dehydration | 28 (17.7) |
| Respiratory distress/infection | 24 (13.7) |
| Fever/sepsis | 17 (9.7) |
| Pain control | 16 (9.1) |
| Renal dysfunction | 15 (8.6) |
| Chest pain | 15 (8.6) |
| Neurologic dysfunction | 10 (5.7) |
| Percutaneous endoscopic gastrostomy tube complication | 9 (5.1) |
| Radiation mucositis/dermatitis | 9 (5.1) |
| Acute bleeding episode | 7 (4) |
| Urinary tract infection | 5 (2.1) |
| Soft tissue infection | 5 (2.1) |
| Other | 15 (8.6) |
Analysis of hospitalization-associated radiation therapy interruptions by study cohort characteristics
| Univariable model | Multivariable model | |||
|---|---|---|---|---|
| Unadjusted odds ratio (95% confidence interval) | Adjusted odds ratio (95% confidence interval) | |||
| Male | ||||
| Female | 0.77 (0.58-1.03) | .076 | 1.33 (0.93-1.88) | .12 |
| ≥65 | ||||
| <65 | 0.9 (0.67-1.20) | .46 | 1.1 (0.71-1.70) | .68 |
| White | ||||
| African-American | 1.48 (1.10-1.98) | .009* | 1.48 (1.07-2.06) | .018* |
| Other | 1.56 (0.68-3.11) | .24 | 1.49 (0.64-3.06) | .32 |
| Married | ||||
| Unmarried | 1.38 (1.03-1.85) | .032* | 0.4 (0.02-4.36) | .48 |
| High (>$67k) | ||||
| Middle ($34-67k) | 0.98 (0.71-1.37) | .92 | 0.97 (0.69-1.38) | .88 |
| Low (<$34k) | 0.77 (0.52-1.13) | .19 | 0.85 (0.56-1.28) | .43 |
| Metro | ||||
| Rural not by metro | 0.15 (0.01-0.68) | .061 | 0.15 (0.008-0.67) | .058 |
| Rural by metro | 0.52 (0.20-1.09) | .12 | 0.51 (0.20-1.09) | .12 |
| 0-5 | ||||
| 6-10 | 0.83 (0.59-1.17) | .29 | 0.82 (0.57-1.17) | .27 |
| 11-15 | 0.56 (0.32-0.91) | .026* | 0.7 (0.40-1.16) | .18 |
| 16-20 | 1.04 (0.57-1.81) | .88 | 1.26 (0.67-2.24) | .46 |
| 21-30 | 0.71 (0.36-1.27) | .28 | 0.76 (0.38-1.40) | .4 |
| 31-40 | 0.27 (0.043-0.86) | .068 | 0.32 (0.05-1.09) | .13 |
| >40 | 0.48 (0.24-0.87) | .025* | 1.32 (0.46-3.21) | .58 |
| Commercial | ||||
| Medicare | 1.85 (1.34-2.58) | .0002* | 1.7 (1.21-2.39) | .0022* |
| Medicaid/no insurance | 2.73 (1.79-4.11) | < .0001* | 2.05 (1.32-3.15) | .0013* |
| Medicaid | 2.29 (1.28-3.90) | .0034* | 1.56 (0.85-2.73) | .13 |
| No insurance | 3.20 (1.89-5.24) | < .0001* | 2.64 (1.53-4.43) | .0003* |
| Breast | ||||
| Prostate | 1.98 (0.95-4.06) | .061 | 1.73 (0.76-3.89) | .19 |
| Lung | 6.82 (3.86-12.55) | < .0001* | 5.97 (3.22-11.44) | < .0001* |
| Gynecologic | 3.73 (1.79-7.69) | .0004* | 2.57 (1.20-5.40) | .013* |
| Head and neck | 6.77 (3.88-12.34) | < .0001* | 5.6 (2.96-10.93) | < .0001* |
| Gastrointestinal | 3.00 (1.38-6.33) | .0042* | 2.55 (1.13-5.56) | .02* |
| Central nervous system | 2.81 (1.07-6.63) | .024* | 2.71 (1.00-6.60) | .036* |
| Metastasis | 2.41 (1.25-4.69) | .0087* | 3.46 (1.69-7.13) | .0007* |
| Skin | 3.41 (1.30-8.09) | .0076* | 4.37 (1.58-11.01) | .0026* |
| Soft tissue | 2.22 (0.35-8.02) | .3 | 1.94 (0.30-7.23) | .39 |
| Hematologic | 1.59 (0.45-4.37) | .41 | 2.28 (0.63-6.57) | .16 |
| Other | 7.67 (3.89-15.25) | < .0001* | 8.4 (4.07-17.45) | < .0001* |
| Nonwinter (March-October) | ||||
| Winter (November-February) | 0.77 (0.56-1.06) | .11 | 0.81 (0.58-1.12) | .22 |
| 1-20 | ||||
| >20 | 2.18 (1.60-3.02) | < .0001* | 2.23 (1.51-3.34) | < .0001* |
*Denotes statistical significanceasd
Figure 1Geospatial analysis of hospitalization-associated radiation therapy interruption rates, stratified according to patient race. Median household income is mapped at census tract level according to prespecified categories. Greater hospitalization-associated radiation therapy interruption rates are denoted by larger bubbles plotted at ZIP code centroids.
Figure 2Geospatial analysis of hospitalization-associated radiation therapy interruption rates stratified according to patient insurance. Median household income is mapped at census tract level according to prespecified categories. Greater hospitalization-associated radiation therapy interruption rates are denoted by larger bubbles plotted at ZIP code centroids.